oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2019-18-6-140-144oncotomsk-1255Research ArticleСЛУЧАЙ ИЗ КЛИНИЧЕСКОЙ ПРАКТИКИCASE REPORTSКЛИНИЧЕСКИЙ СЛУЧАЙ КОМПЛЕКСНОГО ЛЕЧЕНИЯ МЕТАСТАТИЧЕСКОГО РАКА МОЧЕВОГО ПУЗЫРЯCLINICAL CASE OF MULTIMODALITY TREATMENT OF METASTATIC BLADDER CANCERhttps://orcid.org/0000-0002-1671-1195ЛыковА. В.LykovA. V.

кандидат медицинских наук, доцент кафедры онкологии с курсом урологии; руководитель Областного урологического центра 

SPIN-код: 2108-9194. AuthorID (РИНЦ): 371843Россия, г. Тюмень, 625023, ул. Одесская, 54

Россия, г. Тюмень, 625048, ул. Шиллера, 12

MD, PhD, Assistant Professor of Oncology with a course of urology; Head of the Regional Urological Center 

54, Odesskaya st., tyumen-625023, Russia

12, schiller st., tyumen-625048, Russia

lykov_av@mail.ruhttps://orcid.org/0000-0002-9240-3792ЗнобищевВ. Г.ZnobishchevV. G.

врач-уролог отделения онкологии

SPIN-код: 4204-4073. AuthorID (РИНЦ): 1018611Россия, г. Тюмень, 625048, ул. Шиллера, 12 

MD, Physician 

12, schiller st., tyumen-625048, Russia 

unksent@mail.ruПоповИ. Б.PopovI. B.

кандидат медицинских наук, генеральный директор-главный врач

AuthorID (РИНЦ): 744820 Россия, г. Тюмень, 625048, ул. Шиллера, 12 

12, schiller st., tyumen-625048, Russia 

https://orcid.org/0000-0002-5071-0604КельнА. А.KelnA. A.

ассистент кафедры онкологии с курсом урологии; врач-уролог отделения онкологии 

SPIN-код: 9633-0276. AuthorID (РИНЦ): 971115Россия, г. Тюмень, 625023, ул. Одесская, 54 

Россия, г. Тюмень, 625048, ул. Шиллера, 12 

MD, Assistant of Oncology with a course of urology; Physician of Oncourology Department 

54, Odesskaya st., tyumen-625023, Russia 

12, schiller st., tyumen-625048, Russia 

ФГБОУ ВО «Тюменский государственный медицинский университет» Минздрава России, АО МСЧ «Нефтяник»РоссияTyumen State Medical University of the Ministry of Healthcare of Russia, Joint-stock company Medical unit «Neftyanik»Russian FederationАО МСЧ «Нефтяник»РоссияJoint-stock company Medical unit «Neftyanik»Russian Federation201907012020186140144Copyright © Лыков А.В., Знобищев В.Г., Попов И.Б., Кельн А.А., 20202020Лыков А.В., Знобищев В.Г., Попов И.Б., Кельн А.А.Lykov A.V., Znobishchev V.G., Popov I.B., Keln A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1255рак мочевого пузыряуротелиальный ракхирургическое лечениеметастазэктомияциторедукцияbladder cancerurothelial cancersurgical treatmentmetastasectomycytoreductionclinical caseReferencesРак мочевого пузыря. Клинические рекомендации. 2018. [Интернет]. URL: https://oncology-association.ru/files/clinical-guidelines_adults%C2%A0-%20projects2018/rak-mochevogo-puzyrya_pr2018.pdf (дата обращения: 5.02.2019).Bladder cancer. Clinical recommendations. 2018. [Internet]. URL: https://oncology-association.ru/files/clinical-guidelines_adults%C2%A0-%20projects2018/rak-mochevogopuzyrya_pr2018.pdf (cited 5.02.2019). (in Russian).Лыков А.В., Кельн А.А., Зырянов А.В., Пономарев А.В. Проблемы хирургических осложнений радикальной цистэктомии: опыт одной клиники. Уральский медицинский журнал. 2017; (2): 109–113.Lykov A.V., Keln A.A., Zyryanov A.V., Ponomaryov A.V. Problems of surgical complications of radical cystectomy: experience one clinic. Ural medical journal. 2017; (2): 109–113. (in Russian).Кельн А.А. Анализ результатов радикального лечения пациентов с мышечно-инвазивным раком мочевого пузыря. Университетская медицина Урала. 2016; 2(5): 27–29.Kel’n A.A. Analysis of the results of radical treatment of patients with muscle-invasive bladder cancer. Universitetskaya meditsina Urala. 2016; 2(5): 27–29. (in Russian).Rosenberg J.E., Carroll P.R., Small E.J. Update on chemotherapy for advanced bladder cancer. J Urol. 2005 Jul; 174(1): 14–20. doi: 10.1097/01.ju.0000162039.38023.5f.Rosenberg J.E., Carroll P.R., Small E.J. Update on chemotherapy for advanced bladder cancer. J Urol. 2005 Jul; 174(1): 14–20. doi: 10.1097/01.ju.0000162039.38023.5f.Muscle-invasive and Metastatic Bladder Cancer» EAU Guidelines, 2018 [Internet]. URL: https://uroweb.org/guideline/bladder-cancer-muscleinvasive-and-metastatic (cited 5.02.2019).Muscle-invasive and Metastatic Bladder Cancer» EAU Guidelines, 2018 [Internet]. URL: https://uroweb.org/guideline/bladder-cancer-muscleinvasive-and-metastatic (cited 5.02.2019).von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., Moore M.J., Zimmermann A., Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005 Jul 20; 23(21): 4602–8. doi: 10.1200/JCO.2005.07.757.von der Maase H., Sengelov L., Roberts J.T., Ricci S., Dogliotti L., Oliver T., Moore M.J., Zimmermann A., Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005 Jul 20; 23(21): 4602–8. doi: 10.1200/JCO.2005.07.757.Bellmunt J., Théodore C., Demkov T., Komyakov B., Sengelov L., Daugaard G., Caty A., Carles J., Jagiello-Gruszfeld A., Karyakin O., Delgado F.M., Hurteloup P., Winquist E., Morsli N., Salhi Y., Culine S., von der Maase H. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20; 27(27): 4454–61. doi: 10.1200/JCO.2008.20.5534.Bellmunt J., Théodore C., Demkov T., Komyakov B., Sengelov L., Daugaard G., Caty A., Carles J., Jagiello-Gruszfeld A., Karyakin O., Delgado F.M., Hurteloup P., Winquist E., Morsli N., Salhi Y., Culine S., von der Maase H. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009 Sep 20; 27(27): 4454–61. doi: 10.1200/JCO.2008.20.5534.Powles T., Eder J.P., Fine G.D., Braiteh F.S., Loriot Y., Cruz C., Bellmunt J., Burris H.A., Petrylak D.P., Teng S.L., Shen X., Boyd Z., Hegde P.S., Chen D.S., Vogelzang N.J. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov 27; 515(7528): 558–62. doi: 10.1038/nature13904.Powles T., Eder J.P., Fine G.D., Braiteh F.S., Loriot Y., Cruz C., Bellmunt J., Burris H.A., Petrylak D.P., Teng S.L., Shen X., Boyd Z., Hegde P.S., Chen D.S., Vogelzang N.J. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014 Nov 27; 515(7528): 558–62. doi: 10.1038/nature13904.Rosenberg J.E., Hoffman-Censits J., Powles T., van der Heijden M.S., Balar A.V., Necchi A., Dawson N., O’Donnell P.H., Balmanoukian A., Loriot Y., Srinivas S., Retz M.M., Grivas P., Joseph R.W., Galsky M.D., Fleming M.T., Petrylak D.P., Perez-Gracia J.L., Burris H.A., Castellano D., Canil C., Bellmunt J., Bajorin D., Nickles D., Bourgon R., Frampton G.M., Cui N., Mariathasan S., Abidoye O., Fine G.D., Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7; 387(10031): 1909–20. doi: 10.1016/S0140-6736(16)00561-4.Rosenberg J.E., Hoffman-Censits J., Powles T., van der Heijden M.S., Balar A.V., Necchi A., Dawson N., O’Donnell P.H., Balmanoukian A., Loriot Y., Srinivas S., Retz M.M., Grivas P., Joseph R.W., Galsky M.D., Fleming M.T., Petrylak D.P., Perez-Gracia J.L., Burris H.A., Castellano D., Canil C., Bellmunt J., Bajorin D., Nickles D., Bourgon R., Frampton G.M., Cui N., Mariathasan S., Abidoye O., Fine G.D., Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7; 387(10031): 1909–20. doi: 10.1016/S0140-6736(16)00561-4.Bellmunt J., de Wit R., Vaughn D.J., Fradet Y., Lee J.L., Fong L., Vogelzang N.J., Climent M.A., Petrylak D.P., Choueiri T.K., Necchi A., Gerritsen W., Gurney H., Quinn D.I., Culine S., Sternberg C.N., Mai Y., Poehlein C.H., Perini R.F., Bajorin D.F.; KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 Mar 16; 376(11): 1015–1026. doi: 10.1056/NEJMoa1613683.Bellmunt J., de Wit R., Vaughn D.J., Fradet Y., Lee J.L., Fong L., Vogelzang N.J., Climent M.A., Petrylak D.P., Choueiri T.K., Necchi A., Gerritsen W., Gurney H., Quinn D.I., Culine S., Sternberg C.N., Mai Y., Poehlein C.H., Perini R.F., Bajorin D.F.; KEYNOTE-045 Investigators. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017 Mar 16; 376(11): 1015–1026. doi: 10.1056/NEJMoa1613683.Sharma P., Retz M., Siefker-Radtke A., Baron A., Necchi A., Bedke J., Plimack E.R., Vaena D., Grimm M.O., Bracarda S., Arranz J.Á., Pal S., Ohyama C., Saci A., Qu X., Lambert A., Krishnan S., Azrilevich A., Galsky M.D. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar; 18(3): 312–322. doi: 10.1016/S1470-2045(17)30065-7.Sharma P., Retz M., Siefker-Radtke A., Baron A., Necchi A., Bedke J., Plimack E.R., Vaena D., Grimm M.O., Bracarda S., Arranz J.Á., Pal S., Ohyama C., Saci A., Qu X., Lambert A., Krishnan S., Azrilevich A., Galsky M.D. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar; 18(3): 312–322. doi: 10.1016/S1470-2045(17)30065-7.Iwamoto H., Izumi K., Shimura Y., Natsagdorj A., Maolake A., Takezawa Y., Nohara T., Shigehara K., Kadono Y., Mizokami A. Metastasectomy improves survival in patients with metastatic urothelial carcinoma. Anticancer Res. 2016 Oct; 36(10): 5557–5561. doi: 10.21873/anticanres.11140.Iwamoto H., Izumi K., Shimura Y., Natsagdorj A., Maolake A., Takezawa Y., Nohara T., Shigehara K., Kadono Y., Mizokami A. Metastasectomy improves survival in patients with metastatic urothelial carcinoma. Anticancer Res. 2016 Oct; 36(10): 5557–5561. doi: 10.21873/anticanres.11140.Abe T., Matsumoto R., Shinohara N. Role of surgical consolidation in metastatic urothelial carcinoma. Curr Opin Urol. 2016 Nov; 26(6): 573–80. doi: 10.1097/MOU.0000000000000329.Abe T., Matsumoto R., Shinohara N. Role of surgical consolidation in metastatic urothelial carcinoma. Curr Opin Urol. 2016 Nov; 26(6): 573–80. doi: 10.1097/MOU.0000000000000329.Matsuguma H., Yoshino I., Ito H., Goya T., Matsui Y., Nakajima J., Ikeda N., Okumura S., Shiono S., Nomori H.; Metastatic Lung Tumor Study Group of Japan. Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma? Ann Thorac Surg. 2011 Aug; 92(2): 449–53. doi: 10.1016/j.athoracsur.2011.03.097.Matsuguma H., Yoshino I., Ito H., Goya T., Matsui Y., Nakajima J., Ikeda N., Okumura S., Shiono S., Nomori H.; Metastatic Lung Tumor Study Group of Japan. Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma? Ann Thorac Surg. 2011 Aug; 92(2): 449–53. doi: 10.1016/j.athoracsur.2011.03.097.Patel V., Collazo Lorduy A., Stern A., Fahmy O., Pinotti R., Galsky M.D., Gakis G. Survival after metastasectomy for metastatic urothelial carcinoma: a systematic review and meta-analysis. Bladder Cancer. 2017 Apr 27; 3(2): 121–132. doi: 10.3233/BLC-170108.Patel V., Collazo Lorduy A., Stern A., Fahmy O., Pinotti R., Galsky M.D., Gakis G. Survival after metastasectomy for metastatic urothelial carcinoma: a systematic review and meta-analysis. Bladder Cancer. 2017 Apr 27; 3(2): 121–132. doi: 10.3233/BLC-170108.Abufaraj M., Dalbagni G., Daneshmand S., Horenblas S., Kamat A.M., Kanzaki R., Zlotta A.R., Shariat S.F. The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. Eur Urol. 2018 Apr; 73(4): 543–557. doi: 10.1016/j.eururo.2017.09.030.Abufaraj M., Dalbagni G., Daneshmand S., Horenblas S., Kamat A.M., Kanzaki R., Zlotta A.R., Shariat S.F. The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. Eur Urol. 2018 Apr; 73(4): 543–557. doi: 10.1016/j.eururo.2017.09.030.Cowles R.S., Johnson D.E., McMurtrey M.J. Long-term results following thoracotomy for metastatic bladder cancer. Urology. 1982 Oct; 20(4): 390–2.Cowles R.S., Johnson D.E., McMurtrey M.J. Long-term results following thoracotomy for metastatic bladder cancer. Urology. 1982 Oct; 20(4): 390–2.Siefker-Radtke A.O., Walsh G.L., Pisters L.L., Shen Y., Swanson D.A., Logothetis C.J., Millikan R.E. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 2004; 171: 145–148. doi: 10.1097/01.ju.0000099823.60465.e6.Siefker-Radtke A.O., Walsh G.L., Pisters L.L., Shen Y., Swanson D.A., Logothetis C.J., Millikan R.E. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol 2004; 171: 145–148. doi: 10.1097/01.ju.0000099823.60465.e6.Lehmann J., Suttmann H., Albers P., Volkmer B., Gschwend J.E., Fechner G., Spahn M., Heidenreich A., Odenthal A., Seif C., Nürnberg N., Wülfing C., Greb C., Kälble T., Grimm M.O., Fieseler C.F., Krege S., Retz M., Schulte-Baukloh H., Gerber M., Hack M., Kamradt J., Stöckle M. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol. 2009 Jun; 55(6): 1293–9. doi: 10.1016/j.eururo.2008.11.039.Lehmann J., Suttmann H., Albers P., Volkmer B., Gschwend J.E., Fechner G., Spahn M., Heidenreich A., Odenthal A., Seif C., Nürnberg N., Wülfing C., Greb C., Kälble T., Grimm M.O., Fieseler C.F., Krege S., Retz M., Schulte-Baukloh H., Gerber M., Hack M., Kamradt J., Stöckle M. Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol. 2009 Jun; 55(6): 1293–9. doi: 10.1016/j.eururo.2008.11.039.Nakagawa T., Taguchi S., Kanatani A., Kawai T., Ikeda M., Urakami S., Matsumoto A., Komemushi Y., Miyakawa J., Yamada D., Suzuki M., Enomoto Y., Nishimatsu H., Kondo Y., Nagase Y., Hirano Y., Okaneya T., Tanaka Y., Miyazaki H., Fujimura T., Fukuhara H., Kume H., Igawa Y., Homma Y. Oncologic Outcome of Metastasectomy for Urothelial Carcinoma: Who Is the Best Candidate? Ann Surg Oncol. 2017 Sep; 24(9): 2794–2800.Nakagawa T., Taguchi S., Kanatani A., Kawai T., Ikeda M., Urakami S., Matsumoto A., Komemushi Y., Miyakawa J., Yamada D., Suzuki M., Enomoto Y., Nishimatsu H., Kondo Y., Nagase Y., Hirano Y., Okaneya T., Tanaka Y., Miyazaki H., Fujimura T., Fukuhara H., Kume H., Igawa Y., Homma Y. Oncologic Outcome of Metastasectomy for Urothelial Carcinoma: Who Is the Best Candidate? Ann Surg Oncol. 2017 Sep; 24(9): 2794–2800.

The authors declare that there are no conflicts of interest present.